Key statistics dashboard for Onconetix, Inc. (ONCO). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Onconetix, Inc. operates as a biotechnology and pharmaceutical firm, committed to pioneering and bringing to market innovative treatments aimed at resolving critical health issues worldwide. The company's product lineup includes Entadfi, an FDA-cleared, once-daily oral medication. This prescription drug combines finasteride and tadalafil to manage benign prostatic hyperplasia (BPH).
Stock Data
| Price | $0.66 |
| Market Cap | $2M |
| Enterprise Value | -$3.4M |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.08 |
| Price / Book | 0.11 |
| P/S | 3.68 |
| EV/EBITDA | 0.34 |
| EV/Sales | -5.23 |
| EV/FCF | 0.33 |
| P/FCF | -0.23 |
| Earnings Yield | -685.30% |
| FCF Yield | -433.51% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 80.40% |
| EBIT Margin | -1530.56% |
| EBITDA Margin | -1528.68% |
| Operating Margin | -1265.55% |
| Net Margin | -1578.79% |
| Return on Equity | -91.95% |
| Return on Assets | -62.07% |
| Return on Invested Capital | -59.84% |
| Return on Capital Employed | -60.62% |
Financial Health
| Current Ratio | 2.21 |
| Quick Ratio | 2.14 |
| Cash Ratio | 2.02 |
| Debt / Equity | 0.01 |
| Debt / Assets | 1.14% |
| Net Debt / EBITDA | 0.58 |
| Interest Coverage | -26.28 |
Per-Share Data
| Revenue per share | 0.29 |
| Book Value per share | 6.01 |
| Cash per share | 2.65 |
| FCF per share | -4.60 |
| Tangible Book Value per share | 1.72 |
| Dividend per share | 0.00 |
Related companies: AZTR · ENVB · INDP · JSPR · PTIX · REVB · SCNI
Explore sector: Healthcare · Biotechnology
More sections of ONCO: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks